Liposomal Formulation of Combinational Antibiotics

Back to all technologies
Download as PDF
2018-ZHOU-68205
Liposomal formulations have been developed for single drugs such as ciprofloxacin but not for combinational antibiotics. Liposomal formulations have shown significant less irritation to the respiratory tract and much better safety in previous clinical trials. Developing liposomal formulations for combinational antibiotics might be beneficial for the treatment of respiratory infections.

Researchers at Purdue University have developed a new liposomal formulation of combinational antibiotics for the treatment of respiratory infections. This new formulation incorporates two synergistic antibiotics to enable maximum bacteria killing against resistant pathogens while significantly reducing irritation to the respiratory tract.

Advantages:
-Maximum bacteria killing against resistant pathogens
-Reduce resistance development

Potential Applications:
-Treatment of respiratory infections
-Eradication of Pseudomonas aeruginosa
Oct 30, 2020
NATL-Patent
United States
(None)
(None)

Apr 30, 2019
PCT-Patent
WO
(None)
(None)

Apr 13, 2019
NATL-Patent
Europe
(None)
(None)

Apr 30, 2018
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org